Verifique sus conocimientos sobre las exploraciones complementarias (III)

Ésta es la tercera entrega de una serie sobre las pruebas complementarias que se inició en el ejemplar de Nursing2007 de abril. Nuestra intención es completar el apartado sobre el esqueleto óseo. La importancia de la radiología convencional osteoarticular y su uso generalizado hacen que consideremos indicado profundizar en algunos aspectos ya mencionados en la anterior entrega e introducir algunos conceptos nuevos que nos permitan conocer a fondo este apartado. Una vez más recordamos la importancia que para los diplomados/as en enfermería tiene la posibilidad de conocer estas exploraciones, y más en el caso que nos ocupa, por lo habitual del contacto con estas técnicas en la práctica diaria de muchos de nosotros. El objetivo es conocer la preparación y las características generales de la prueba, así como las curas posteriores a ella para satisfacer las necesidades del paciente durante el proceso diagnóstico. En nuestro entrenamiento para aprender a identificar las imágenes es interesante ayudarse de personas que, como los técnicos especialistas en radiología y los médicos especialistas radiólogos, visualizan continuamente exploraciones radiológicas y nos pueden ayudar a aplicar los conocimientos y las pautas de interpretación de imágenes radiológicas que exponemos en esta serie.

Verifique sus conocimientos sobre las exploraciones complementarias (III)

Ésta es la tercera entrega de una serie sobre las pruebas complementarias que se inició en el ejemplar de Nursing2007 de abril. Nuestra intención es completar el apartado sobre el esqueleto óseo. La importancia de la radiología convencional osteoarticular y su uso generalizado hacen que consideremos indicado profundizar en algunos aspectos ya mencionados en la anterior entrega e introducir algunos conceptos nuevos que nos permitan conocer a fondo este apartado. Una vez más recordamos la importancia que para los diplomados/as en enfermería tiene la posibilidad de conocer estas exploraciones, y más en el caso que nos ocupa, por lo habitual del contacto con estas técnicas en la práctica diaria de muchos de nosotros. El objetivo es conocer la preparación y las características generales de la prueba, así como las curas posteriores a ella para satisfacer las necesidades del paciente durante el proceso diagnóstico. En nuestro entrenamiento para aprender a identificar las imágenes es interesante ayudarse de personas que, como los técnicos especialistas en radiología y los médicos especialistas radiólogos, visualizan continuamente exploraciones radiológicas y nos pueden ayudar a aplicar los conocimientos y las pautas de interpretación de imágenes radiológicas que exponemos en esta serie.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

PURPOSE: The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. METHODS: Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. RESULTS: After a median follow-up of 9.5 years, 10-year OS rates in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4) arms were 67.1% versus 71.7% (hazard ratio [HR], 0.85; P = .043) in the whole population, 79.5% versus 78.4% for stage II (HR, 1.00; P = .980), and 59.0% versus 67.1% for stage III (HR, 0.80; P = .016) disease. Ninety-five patients (9.4%) had MMR-deficient (dMMR) tumors, and 94 (10.4%) had BRAF mutation. BRAF mutation was not prognostic for OS (P = .965), but dMMR was an independent prognostic factor (HR, 2.02; 95% CI, 1.15 to 3.55; P = .014). HRs for DFS and OS benefit in the FOLFOX4 arm were 0.48 (95% CI, 0.20 to 1.12) and 0.41 (95% CI, 0.16 to 1.07), respectively, in patients with stage II to III dMMR and 0.50 (95% CI, 0.25 to 1.00) and 0.66 (95% CI, 0.31 to 1.42), respectively, in those with BRAF mutation. CONCLUSION: The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer. These updated results support the use of FOLFOX in patients with stage III disease, including those with dMMR or BRAF mutation.

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

PURPOSE: This multicenter phase III study evaluated the efficacy and safety of lapatinib, an epidermal growth factor receptor/ErbB2 inhibitor, administered concomitantly with chemoradiotherapy and as maintenance monotherapy in patients with high-risk surgically treated squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with resected stage II to IVA SCCHN, with a surgical margin ≤ 5 mm and/or extracapsular extension, were randomly assigned to chemoradiotherapy (66 Gy total radiation dose and cisplatin 100 mg/m(2) per day administered on days 1, 22, and 43) plus placebo or lapatinib (1,500 mg per day) before and during chemoradiotherapy, followed by 12 months of maintenance monotherapy. RESULTS: Six hundred eighty-eight patients were enrolled (lapatinib, n = 346; placebo, n = 342). With a median follow-up time of 35.3 months, the study ended early because of the apparent plateauing of disease-free survival (DFS) events. Median DFS assessed by an independent review committee was 53.6 months and not reached for lapatinib and placebo, respectively (hazard ratio, 1.10; 95% CI, 0.85 to 1.43). Investigator-assessed results confirmed the independent review committee assessment. No significant differences in DFS by human papillomavirus status or overall survival were observed between treatment arms. Similar numbers of patients in both treatment arms experienced adverse events (AEs), with more patients in the lapatinib arm than the placebo arm experiencing serious AEs (48% v 40%, respectively). The most commonly observed treatment-related AEs were diarrhea and rash, both predominantly in the lapatinib arm. CONCLUSION: Addition of lapatinib to chemoradiotherapy and its use as long-term maintenance therapy does not offer any efficacy benefits and had additional toxicity compared with placebo in patients with surgically treated high-risk SCCHN.

DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.

PURPOSE: Prospective-retrospective assessment of theTOP1gene copy number andTOP1mRNA expression as predictive biomarkers for adjuvant irinotecan in stage II/III colon cancer. EXPERIMENTAL DESIGN: Formalin-fixed, paraffin-embedded tissue microarrays were obtained from an adjuvant colon cancer trial (PETACC3) where patients were randomized to 5-fluorouracil/folinic acid with or without additional irinotecan.TOP1copy number status was analyzed by fluorescencein situhybridization (FISH) using aTOP1/CEN20 dual-probe combination.TOP1mRNA data were available from previous analyses. RESULTS: TOP1FISH and follow-up data were obtained from 534 patients.TOP1gain was identified in 27% using a single-probe enumeration strategy (≥4TOP1signals per cell) and in 31% when defined by aTOP1/CEN20 ratio ≥ 1.5. The effect of additional irinotecan was not dependent onTOP1FISH status.TOP1mRNA data were available from 580 patients with stage III disease. Benefit of irinotecan was restricted to patients characterized byTOP1mRNA expression ≥ third quartile (RFS: HRadjusted, 0.59;P= 0.09; OS: HRadjusted, 0.44;P= 0.03). The treatment byTOP1mRNA interaction was not statistically significant, but in exploratory multivariable fractional polynomial interaction analysis, increasingTOP1mRNA values appeared to be associated with increasing benefit of irinotecan. CONCLUSIONS: In contrast to theTOP1copy number, a trend was demonstrated for a predictive property ofTOP1mRNA expression. On the basis ofTOP1mRNA, it might be possible to identify a subgroup of patients where an irinotecan doublet is a clinically relevant option in the adjuvant setting of colon cancer.Clin Cancer Res; 22(7); 1621-31. ©2015 AACR.

Aportació al coneixement florístic de les Guilleries i del Collsacabra (Catalunya Oriental), III

En la present nota indiquem un seguit de novetats corològiques per a la flora vascular dels massissos de les Guilleries i del Collsacabra.

Estudos de QSAR baseados em dados de atividade biológica obtidos por microcalorimetria: III interação de m-alcoxifenóis e p-hidroxibenzoatos de alquila com Escherichia coli

QSAR studies based on flow microcalorimetric bioassay data for interaction of homologous series of m-alkoxyphenols and p-hydroxybenzoates with E. coli cells were carried out applying factorial design. Results for both series showed a linear relationship between log(dose)max and log Po/w. Analysis of these data allows the identification of contributions toward the derived bioactivity from the parent structures (the molecule minus n-CH2 groups present in the side-chain) and the lipophilic groups, CH2. These results are discussed with respect to drug quantitative structure-relationship.

Sjungande Finland III, Det

Huom! Kirjan sisällysluettelo viittaa laulujen alkusanoihin.

Symfoni III

Mukana myös kaksi keskeneräistä 4-kätistä pianosovitusta I osasta, vanhempi versio II osasta, keskeneräinen versio II osasta sekä II osan orkesteristemmat.

Adsorção do complexo H[Ru(III)Cl2(H2EDTA)] sobre a superfície da sílica gel modificada com [3-(2-aminoetil) aminopropil]trimetoxissilano em soluções etanólicas

Silica gel was functionalized with [3-(2-aminoethyl)aminopropyl]trimethoxysilane group (SF-AEATS) and the characterization by chemical analysis (N) and infrared spectroscopy confirmed the functionalization. The capacity of the modified silica to adsorb the complex Ru(III)-EDTA from ethanolic solution was studied. The selectivity coefficients of the complex formed on the support obtained was (Gñ), 2,07 x 10(4) L/mol and the average number of ligand bonded by one metal ion on the support (ñ) was ~ 1.

Reações de contração de anel promovidas por sais de tálio(III)

Thallium(III) salts promote a number of different reactions useful in organic synthesis. In this paper, the ring contraction of ketones and olefins, mediated by thallium(III) salts, is exhaustively reviewed.

Ouranós-Gaia. L’espai a Grècia III: anomenar l’espai

Aquesta obra recull les aportacions del III Col·loqui internacional sobre la concepció de l'espai a Grècia "Cel i Terra: anomenar l'espai a Grècia", coorganitzat per la Societat Catalana d'Estudis Clàssics (filial de l’Institut d’Estudis Catalans) i l'ICAC i que va tenir lloc els dies 29 i 30 de novembre del 2010. Es tracta del tercer volum sobre la concepció de l’espai a Grècia editat pel grup de recerca “L’espai segons el veien i el pensaven els grecs”.

Coordenação local do Eu(III) em híbridos orgânicos/inorgânicos emissores de luz branca

Eu3+ luminescence and EXAFS (Extended X-ray Absorption Fine Structure) results are presented for organic-inorganic hybrid gel hosts composed of a siliceous network to which small chains of oxyethylene units are covalently grafted by means of urea bridges. Coordination numbers for Eu3+ ions range from 12.8 to 9.7 with increasing Eu3+ concentration while the Eu3+-first neighbours mean distance is found to be constant at 2.48-2.49 Å in the same concentration range. Emission spectra display a broad band in the green/blue spectral region superposed to narrow lines appearing in the yellow/red region in such a way that for the eyes emission appears white. The broad band is assigned to intrinsic NH groups emission and also to electron-hole recombination in the nanosised siliceous domains. The narrow lines are assigned to intra-4f6, 5D0->7F0-4 Eu3+ transitions and from the energy position of the 7F0-4 levels a mean distance could be calculated for the Eu3+-first neighbours. The calculated results are in good agreement with the experimental ones obtained from EXAFS analysis.